Soleno Therapeutics Stock Analysis
SLNO Stock | USD 58.34 1.12 1.96% |
Soleno Therapeutics is overvalued with Real Value of 46.3 and Target Price of 37.0. The main objective of Soleno Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Soleno Therapeutics is worth, separate from its market price. There are two main types of Soleno Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Soleno Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Soleno Therapeutics is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Soleno Stock trading window is adjusted to America/New York timezone.
Soleno |
Soleno Stock Analysis Notes
About 97.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.79. Soleno Therapeutics last dividend was issued on the 6th of October 2017. The entity had 1:15 split on the 26th of August 2022. Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. Soleno Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people. To find out more about Soleno Therapeutics contact Anish MD at 650 213 8444 or learn more at https://soleno.life.Soleno Therapeutics Investment Alerts
Net Loss for the year was (38.99 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Soleno Therapeutics currently holds about 24.07 M in cash with (24.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.97. | |
Over 97.0% of the company shares are owned by institutional investors | |
Latest headline from investors.com: Soleno Therapeutics Clears Key Benchmark, Hitting 90-Plus RS Rating |
Soleno Therapeutics Upcoming and Recent Events
Earnings reports are used by Soleno Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
19th of March 2024 Upcoming Quarterly Report | View | |
14th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
19th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Soleno Largest EPS Surprises
Earnings surprises can significantly impact Soleno Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-03-06 | 2023-12-31 | -0.27 | -0.33 | -0.06 | 22 | ||
2022-11-09 | 2022-09-30 | -0.91 | -0.76 | 0.15 | 16 | ||
2023-05-09 | 2023-03-31 | -0.72 | -0.88 | -0.16 | 22 |
Soleno Therapeutics Environmental, Social, and Governance (ESG) Scores
Soleno Therapeutics' ESG score is a quantitative measure that evaluates Soleno Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Soleno Therapeutics' operations that may have significant financial implications and affect Soleno Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Soleno Stock Institutional Investors
Shares | State Street Corp | 2024-06-30 | 1 M | Alyeska Investment Group, L.p. | 2024-09-30 | 976.1 K | Fmr Inc | 2024-09-30 | 665.4 K | Holocene Advisors, Lp | 2024-09-30 | 594.4 K | Sofinnova Ventures | 2024-06-30 | 554.4 K | Tcg Crossover Management, Llc | 2024-09-30 | 550 K | Geode Capital Management, Llc | 2024-09-30 | 540.3 K | Samlyn Capital, Llc | 2024-09-30 | 511.8 K | Westfield Capital Management Company, Lp | 2024-09-30 | 495.7 K | Vivo Capital, Llc | 2024-09-30 | 6.3 M | The Carlyle Group Inc | 2024-09-30 | 4.1 M |
Soleno Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.47 B.Soleno Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.23) | (0.24) | |
Return On Capital Employed | (0.24) | (0.26) | |
Return On Assets | (0.22) | (0.23) | |
Return On Equity | (0.25) | (0.26) |
Management Efficiency
Soleno Therapeutics has return on total asset (ROA) of (0.4805) % which means that it has lost $0.4805 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9111) %, meaning that it created substantial loss on money invested by shareholders. Soleno Therapeutics' management efficiency ratios could be used to measure how well Soleno Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to drop to -0.24. In addition to that, Return On Capital Employed is likely to drop to -0.26. At this time, Soleno Therapeutics' Total Assets are very stable compared to the past year. As of the 27th of November 2024, Non Current Assets Total is likely to grow to about 9.9 M, while Non Currrent Assets Other are likely to drop about 141.1 K.Last Reported | Projected for Next Year | ||
Book Value Per Share | 9.55 | 10.03 | |
Tangible Book Value Per Share | 9.02 | 9.47 | |
Enterprise Value Over EBITDA | (13.35) | (12.69) | |
Price Book Value Ratio | 4.21 | 4.43 | |
Enterprise Value Multiple | (13.35) | (12.69) | |
Price Fair Value | 4.21 | 4.43 | |
Enterprise Value | 2 M | 1.9 M |
Leadership effectiveness at Soleno Therapeutics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta (1.44) | Return On Assets (0.48) | Return On Equity (0.91) |
Technical Drivers
As of the 27th of November, Soleno Therapeutics has the Coefficient Of Variation of 754.6, semi deviation of 2.18, and Risk Adjusted Performance of 0.1088. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Soleno Therapeutics, as well as the relationship between them.Soleno Therapeutics Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Soleno Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Soleno Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Soleno Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Soleno Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Soleno Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Soleno Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Soleno Therapeutics Outstanding Bonds
Soleno Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Soleno Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Soleno bonds can be classified according to their maturity, which is the date when Soleno Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
MGM Resorts International Corp BondUS552953CD18 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
Soleno Therapeutics Predictive Daily Indicators
Soleno Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Soleno Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 156420.0 | |||
Daily Balance Of Power | 0.1845 | |||
Rate Of Daily Change | 1.02 | |||
Day Median Price | 56.29 | |||
Day Typical Price | 56.97 | |||
Price Action Indicator | 2.62 | |||
Period Momentum Indicator | 1.12 |
Soleno Therapeutics Corporate Filings
8K | 26th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 19th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 6th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
13A | 24th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F3 | 21st of October 2024 An amendment to the original Schedule 13D filing | ViewVerify |
F3 | 15th of October 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Soleno Therapeutics Forecast Models
Soleno Therapeutics' time-series forecasting models are one of many Soleno Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Soleno Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Soleno Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Soleno Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Soleno shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Soleno Therapeutics. By using and applying Soleno Stock analysis, traders can create a robust methodology for identifying Soleno entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.01 | 0.01 | |
Operating Profit Margin | 0.01 | 0.01 | |
Net Profit Margin | 0.01 | 0.01 | |
Gross Profit Margin | 0.90 | 0.95 |
Current Soleno Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Soleno analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Soleno analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
37.0 | Strong Buy | 8 | Odds |
Most Soleno analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Soleno stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Soleno Therapeutics, talking to its executives and customers, or listening to Soleno conference calls.
Soleno Stock Analysis Indicators
Soleno Therapeutics stock analysis indicators help investors evaluate how Soleno Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Soleno Therapeutics shares will generate the highest return on investment. By understating and applying Soleno Therapeutics stock analysis, traders can identify Soleno Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 14.6 M | |
Common Stock Shares Outstanding | 16.5 M | |
Total Stockholder Equity | 157.5 M | |
Property Plant And Equipment Net | 419 K | |
Cash And Short Term Investments | 169.7 M | |
Cash | 169.7 M | |
Accounts Payable | 3.1 M | |
Net Debt | -169.3 M | |
50 Day M A | 53.1726 | |
Total Current Liabilities | 11.5 M | |
Other Operating Expenses | 41.4 M | |
Non Current Assets Total | 9.3 M | |
Non Currrent Assets Other | 165 K | |
Stock Based Compensation | 5.9 M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.79) | Return On Assets (0.48) | Return On Equity (0.91) |
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.